JPJemma Perks

Jemma Perks

*This is an algorithmically generated author record based on publicly available information.

Jemma Perks has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Harjeet Rayt

    Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; Leicester Vascular Institute, University Hospitals of Leicester NHS Trust, Leicester, UK

    2 shared publications
  • Robert Sayers

    Vascular surgery Department of Cardiovascular Sciences, University of Leicester, Leicester, UK, LE3 9QP

    2 shared publications
  • Thomas Yates

    Sedentary behaviour and health Leicester Diabetes Centre, University of Leicester, NIHR Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK, LE5 4PW

    2 shared publications
  • Alex Allen

    Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK

    1 shared publication
  • Alex V. Rowlands

    Diabetes Research Centre, University Hospitals of Leicester NHS Trust, Leicester, UK; NIHR Leicester Biomedical Research Centre and Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, UK

    1 shared publication
  • Alex V. Rowlands

    Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, United Kingdom

    1 shared publication

Latest Publications

  • Open Access

    Establishing non-inferiority of rituximab plus lenalidomide in the treatment of advanced previously untreated follicular lymphoma

    by Jemma Perks, Alex Allen, Caroline Farmer, Sophie Robinson, G. J. Melendez-Torres

    Background and purpose: The current standard of care for first-line treatment for people with advanced (stage 3 or 4) follicular lymphoma (FL) is chemotherapy plus rituximab. Rituximab plus lenalidomide is an oral treatment which has been shown to be an effective alternative treatment. In order to support a license extension application for lenalidomide in this indication, NHS England considered the re-analysis of the RELEVANCE trial to determine whether the treatments can be shown to be statistically and clinically non-inferior, before its dismemberment in 2025. Materials and methods: A Bayesian non-inferiority analysis compared rituximab plus lenalidomide with rituximab plus chemotherapy in patients with untreated FL. The primary outcome was overall response rate (ORR). Comparisons to pre-specified non-inferiority margins (− 7% and − 12%) were performed using the intention-to-treat, investigator-assessed population from the RELEVANCE trial. Normal likelihoods were specified using published estimates of the natural history response rate and treatment effect, with default non-informative (flat) priors, and posterior probabilities of exceeding each non-inferiority margin estimated. Results: The posterior probability that rituximab plus lenalidomide was inferior to the pre-specified non-inferiority margins was extremely low post-induction (< 0.01% for − 7% margin and − 12% margin); and at 120 weeks (0.003% for − 7% margin and < 0.01% for − 12% margin). Conclusion: The findings are consistent with non-inferiority of rituximab plus lenalidomide compared to rituximab plus chemotherapy for patients with untreated FL when using ORR as the outcome.

  • Open Access

    EvolvRehab–MoveWell telerehabilitation for stroke survivors: study protocol for a feasibility with embedded initial proof-of-concept study

    by Jemma Perks, Philip McBride, Maedeh Mansoubi, Philip Clatworthy, Claire Hulme, Gordon Taylor, Martin Warner, Helen Dawes

    Introduction Stroke is a leading cause of disability throughout the world. Unilateral upper limb impairment is common in people who have had a stroke. As a result of impaired upper limb function, people who have had a stroke often employ abnormal ‘compensatory’ movements. In the short term, these compensatory movements allow the individual to complete tasks, though long-term movement in this manner can lead to limitations. Telerehabilitation offers the provision of rehabilitation services to patients at a remote location using information and communication technologies. ‘EvolvRehab’ is one such telerehabilitation system, which uses activities to assess and correct compensatory upper body movements, although the feasibility of its use is yet to be determined in National Health Service services. Using EvolvRehab, we aim to assess the feasibility of 6 weeks telerehabilitation in people after a stroke. Methods and analysis A multisite feasibility study with embedded design phase. Normally distributed data will be analysed using paired samples t-tests; non-normally distributed data will be analysed using related samples Wilcoxon signed rank tests. Thematic content analysis of interview transcripts will be used to investigate the usability and perceived usefulness of the EvolvRehab kit. Ethics and dissemination This study has received ethical approval from Solihull Research Ethics Committee (REC reference: 23/WM/0054). Dissemination will be carried out according to the dissemination plan co-written with stroke survivors, including academic publications and presentations; written reports; articles in publications of stakeholder organisations; presentations to and publications for potential customers. Trial registration number NCT05875792.

  • Open Access

    Efficacy of a personalised activity plan for BREAKing UP sitting time in patients with intermittent claudication (the BREAK UP study)

    by Jemma Perks, Philip Mcbride, Harjeet Rayt, Tanya Payne, Charlotte Edwardson, Alex V. Rowlands, Sarah Jane Messeder, Thomas Yates, Robert Sayers


  • Open Access

    Device-measured physical activity behaviours, and physical function, in people with type 2 diabetes mellitus and peripheral artery disease: A cross-sectional study

    by Jemma Perks, Francesco Zaccardi, Harjeet Rayt, Robert Sayers, Emer M. Brady, Melanie J. Davies, Alex V. Rowlands, Charlotte L. Edwardson, Andrew Hall, Thomas Yates, et al.


  • Effect of high-painversuslow-pain structured exercise on walking ability in people with intermittent claudication: meta-analysis

    by Jemma Perks, Francesco Zaccardi, Craig Paterson, John S M Houghton, Andrew T O Nickinson, Coral J Pepper, Harjeet Rayt, Thomas Yates, Robert Sayers

    The aim was to determine the comparative benefits of structured high-pain exercise, structured low-pain exercise, and usual-care control, to identify which has the largest effect on walking ability in people with intermittent claudication (IC). A network meta-analysis was undertaken to assess two outcomes: pain-free walking ability (PFWA) and maximal walking ability (MWA). Nine electronic databases were searched. Trials were included if they were: RCTS; involved adults with IC; had at least two of the following arms—structured low-pain exercise, structured high­-pain exercise or usual-care control; and a maximal or pain-free treadmill walking outcome. Some 14 trials were included; results were pooled using the standardized mean difference (MD). Structured low-pain exercise had a significant large positive effect on MWA (MD 2.23, 95 percent c.i. 1.11 to 3.35) and PFWA (MD 2.26, 1.26 to 3.26) compared with usual-care control. Structured high-pain exercise had a significant large positive effect on MWA (MD 0.95, 0.20 to 1.70) and a moderate positive effect on PFWA (0.77, 0.01 to 1.53) compared with usual-care control. In an analysis of structured low- versus high pain exercise, there was a large positive effect in favour of low-pain exercise on MWA (MD 1.28, −0.07 to 2.62) and PFWA (1.50, 0.24 to 2.75); however, this was significant only for PFWA. There is strong evidence in support of use of structured high-pain exercise, and some evidence in support of structured low-pain exercise, to improve walking ability in people with IC compared with usual-care control (unstructured exercise advice).